Should You Buy Tarsus Pharmaceuticals Inc (TARS) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
Buy now for a near-term rebound setup. TARS is deeply oversold (RSI_6 ~19) and trading right on key support (~64.03) after a mild pullback, while options positioning is aggressively call-skewed (bullish) and hedge funds are meaningfully increasing exposure. With Wall Street’s newer coverage leaning optimistic (two $100 targets) and no negative news flow this week, the risk/reward favors an impatient entry here rather than waiting for a “perfect” pullback.
Technical Analysis
Price/levels: Post-market 64.54, sitting just above S1 64.033 (immediate support). Next downside support is S2 61.358; upside resistance begins at Pivot 68.363 then R1 72.693.
Momentum: RSI_6 at 19.241 signals extreme oversold conditions, which often precede a reflex bounce.
Trend: MACD histogram at -0.94 remains below zero (bearish), but it is “negatively contracting,” implying downside momentum is fading.
Moving averages: Converging MAs suggest the selloff may be stabilizing rather than accelerating.
Pattern stats provided: Similar candlestick-pattern analysis indicates ~70% odds of a +2.09% move next day and +9.59% next week, supporting a short-term rebound bias from this support zone.
Analyst Ratings and Price Target Trends
Recent trend: Ratings skew more bullish recently. Barclays initiated Overweight with a $100 target (2025-12-08) and Mizuho initiated Outperform with a $100 target (2025-11-20), highlighting Xdemvy’s commercial potential and projecting >$2B peak sales. Goldman Sachs remains Neutral and raised its target to $51 from $45 (2025-11-06).
Wall Street pros: Strong commercial product thesis (Xdemvy), large peak-sales potential, and improving specialty pharma sentiment.
Wall Street cons: Not all analysts agree on upside at current levels (Goldman Neutral with a far lower target), reflecting valuation/execution uncertainty and ongoing losses.
Influential/congress trades: No recent congress trading data available; insider trend is reported neutral (no significant activity last month).
Wall Street analysts forecast TARS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 84.6 USD with a low forecast of 51 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast TARS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 84.6 USD with a low forecast of 51 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 65.710
Current: 65.710
